Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology

Reuters

May 20

Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology

Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2536651074"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536651074\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536651074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536651074","market":"nz","top_or_hot":-1,"title":"Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValue Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-20 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00806","symbol_name":"惠理集团","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL2hCrN6:1","article_id":"2536651074","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536651074","pubTimestamp":1747703000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00806":"惠理集团","BK1156":"资产管理与托管银行"},"translate_title":"惠理集团领投Phase Scientific 3400万美元A轮投资，推进尿液诊断技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00806":0.9},"content_text":"Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n    \n\n        Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}